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INTRODUCTION
Despite major advances in transplant medicine, antibody-me-
diated rejection (AMR) remains one of the major barriers to suc-
cessful long-term outcomes.1 Traditional treatments for AMR, 
such as plasmapheresis (PP), intravenous immunoglobulin 
(IVIg), and rituximab have provided suboptimal results. Further-
more, these strategies do not deplete plasma cells (B-lympho-
cyte lineage cells) that produce antibodies.2 Recent studies have 
demonstrated that the proteasome inhibitor bortezomib reduc-
es antibodies by depleting antibody-producing plasma cells; 
thus, bortezomib has been effectively used to treat AMR epi-
sodes refractory to traditional AMR therapies.3-7 
Bortezomib is a proteasome inhibitor that induces the apop-
tosis of plasma cells and was approved by the Food and Drug 
Administration for the treatment of multiple myeloma in 2008.8 
Recently, it has been used to reduce HLA antibodies either be-
fore transplantation or as treatment for AMR. Studies on bort-
ezomib in the transplant field have focused on donor-specific 
anti-HLA antibodies (DSHA).3-5,9,10 However, in view of its ac-
tion mechanism as a proteasome inhibitor, its effect may not 
be limited to anti-HLA antibodies,3,4 and in fact, bortezomib 
has been used to treat disorders other than multiple myelo-
ma.11,12 Therefore, the aim of this study was to investigate the 
effect of bortezomib on AMR caused by various types of anti-
bodies.
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MATERIALS AND METHODS
Subjects
This retrospective study was conducted on ten consecutive pa-
tients diagnosed with AMR and treated with bortezomib from 
November 2011 to April 2014. The study was approved by the 
Institutional Review Board of Severance Hospital, Yonsei Uni-
versity Health System (4-2014-0968).
Diagnosis and treatment of AMR
Patients presented with the defining features of AMR, as de-
scribed by the Banff 2011 meeting report,13 and all ten were re-
fractory to conventional treatment involving PP, IVIg (200 mg/kg 
administered after each PP treatment), and rituximab (single 
dose, 375 mg/m2). Bortezomib was administered after conven-
tional treatment had failed. Each bortezomib cycle consisted of 
four doses of 1.3 mg/m2, which was reduced to 1.0 mg/m2 in 
three patients depending on toxicities, and was administered on 
days 1, 4, 8, and 11. The second cycle of bortezomib was decided 
on case by case after weighing up the advantages and disadvan-
tages in accordance with each patient’s clinical status (antibodies, 
serum creatinine, and side effects). Early-onset AMR was defined 
as an occurrence ≤6 months after kidney transplantation, and 
late-onset AMR was defined as an occurrence at >6 months post-
transplantation. 
Renal function evaluation
Initial renal function was assessed at the time of AMR diagnosis 
based on serum creatinine and the estimated glomerular filtra-
tion rate (eGFR, calculated using the Modification of Diet in Re-
nal Disease formula). Responses to therapy were also assessed 
using serum creatinine and eGFR at 3 months after treatment. 
We evaluated the most recent renal function data and follow-
up duration.
Detection and characterization of antibodies 
DSHA were identified using a single antigen bead assay that 
utilized the multiplex flow-bead microarray method (Lifecodes 
LSA class I and II; Gen-Probe Transplant diagnostics, Inc., 
Stamford, CT, USA). The presence and antigen specificities of 
Abs to HLA-A, -B, -DR, and -DQ were determined. Results are 
expressed as mean fluorescence intensities (MFI). A normal-
ized value of >1000 MFI was considered positive for DSHA. A 
C1q binding assay was performed on all available sera of re-
cipients with DSHA (C1qScreenTM, One Lambda, CA, USA). 
Anti-ABO antibody titers were measured using standard sero-
logical techniques.14 Anti-angiotensin II type 1 receptor (AT1R) 
antibodies were retrospectively evaluated in cases of biopsy-
proven AMR without DSHA. Levels of anti-AT1R antibodies 
(U/mL) were quantified using AT1R assay kits (One Lambda, 
CA, USA), which utilize the enzyme-linked immunosorbent as-
say principle.
Statistical analysis
Statistical analysis was performed using SPSS version 20.0 
(SPSS Inc., Chicago, IL, USA). Wilcoxon’s signed-rank test was 
used to compare differences before and after treatment. p val-
ues of  <0.05 were considered statistically significant. 
RESULTS
Baseline characteristics
Demographic data, including immunologic risk factors are pre-
sented in Table 1. A total of ten patients received bortezomib for 
AMR. Two patients underwent deceased-donor kidney trans-
plantation and eight underwent living-donor kidney transplan-
tation. Five recipients had pre-formed DSHA. Of these five pa-
tients, four received preoperative desensitization, including PP, 
IVIg, and rituximab due to a positive crossmatch or ABO incom-
patibility. The remaining patient received one dose of rituximab 
prior to transplantation. One patient diagnosed with biopsy-
proven AMR in the absence of DSHA was pre-sensitized against 
AT1R. 
Five episodes of AMR developed early (≤6 months post-
transplantation), and four developed late (>6 months post-
transplantation). One patient experienced recurrent AMR (at 
1 and 27 months post-transplantation). 
Histologic data
Histologic data are shown in Table 2. All rejection episodes 
manifested as pure AMR, that is, not as AMR mixed with acute 
cellular rejection. C4d status and biopsy scoring are presented 
according to the Banff 2011 classification. One of six early-on-
set AMR cases and four of five late-onset AMR cases exhibited 
transplant glomerulopathy (cg≥1). 
Clinical outcomes after bortezomib treatment
Treatment outcomes are shown in Table 3 and Fig. 1. Six epi-
sodes of AMR occurred within 6 months of transplantation. 
Patient B (refer to Table 3 for patient details) had anti-B anti-
body and class II HLA antibody. His initial anti-B isoaggluti-
nin titer was low (IgM/IgG 1:32/1:16); however, this increased 
to 1:64/1:256 after transplantation despite postoperative PP 
with IVIg treatment. Patient F had no DSHA yet had a high 
anti-AT1R antibody titer at the time of biopsy. Four patients 
received a standard dose of bortezomib (1.3 mg/m2), and two 
patients (A and F) received a reduced dose (1.0 mg/m2) due to 
toxicities. In all early-onset AMR cases renal function fully re-
covered after bortezomib treatment. The DSHA of two pa-
tients (A and B) disappeared completely after treatment; 
however, although the DSHA of three patients (C, D, and E) 
declined, it was not eradicated. Patient F showed a decline of 
anti-AT1R antibody after treatment.
Five episodes of late-onset AMR were included in this study. 
Patient A experienced recurrent AMR with class I and II HLA 
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antibodies. She received one cycle of bortezomib and recov-
ered well. Three patients (G, H, and I) had class II HLA anti-
bodies, and one patient (J) had class I HLA antibodies. They 
received one to two cycles of bortezomib. Renal function re-
covered in two patients (H and I) after bortezomib treatment; 
however, their antibody titers increased. Patient G received a 
reduced dose (1.0 mg/m2) due to thrombocytopenia.
Overall, a significant improvement in the mean eGFR was 
observed at 3 months after therapy (36.91±22.15 mL/min/1.73 
m2) versus the mean eGFR at the time of diagnosis (17.00±9.25 
mL/min/1.73 m2; p=0.007). 
Bortezomib-related toxicities (thrombocytopenia and pe-
ripheral neuropathy) were all transient and responded to con-
servative management.
DISCUSSION 
Traditional AMR therapeutic strategies have focused on anti-
body removal and B-cell depletion while not directly focusing 
on plasma cell depletion. However, bortezomib is a proteasome 
inhibitor that induces the apoptosis of plasma cells, which are 
the sole source of antibody production.2,5 Patients in this series 
experienced substantial rejection episodes refractory to PP, 
IVIg, and rituximab. Bortezomib was effective against various 
antibody targets, including HLA class I and II, ABO antigen, 
Table 1. Baseline Characteristics of Patients
Patient 
ID
Sex/age
Donor type  
(relation)
HLA  
mismatches
Preoperative immunologic condition
Preoperative 
desensitization
AMR after KT 
(months)
Cross match 
(CDC)
PRA  
(class I/II, %)
Antibodies*
A F/25 LD (parent) 3
T 1:2 (AHG)
B 1:4
100/40 A2 (9618), B13 (4928) PP+IVIG, RIT 1/27
B F/68 LD (offspring) 2 Negative 16/60
DR8 (4981)
Anti-B IgM/IgG (1:32/1:16)
PP+IVIG, RIT 1
C F/45 LD (spouse) 6
T 1:2 (AHG)
B 1:4
10/50 B52 (594), DR15 (2827) PP+IVIG, RIT 0
D M/21 DD 3 Negative 98/13 DQ9 (10485) RIT 1
E M/55 LD (offspring) 3 B 1:16 16/60 B51 (1334), DQ7 (523) PP+IVIG, RIT 0
F M/55 DD 3 Negative 0/33
No DSHA
AT1R Ab >50 U/mL
No 0
G F/38 LD (exchange donor) 4 Negative N/A N/A No 120
H M/28 LD (sibling) 2 Negative N/A N/A No 152
I F/46 LD (sibling) 2 Negative N/A N/A No 113
J F/32 LD (others) 2 Negative N/A N/A No 262
LD, living donor; DD, deceased donor; CDC, complement-dependent cytotoxicity; AHG, anti-human globulin; PRA, panel reactive antibodies; AMR, antibody-me-
diated rejection; PP, plasmapheresis; IVIG, intravenous immunoglobulin; RIT, rituximab; KT, kidney transplantation; DSHA, donor specific anti-HLA antibodies; 
AT1R Ab, angiotensin II type 1 receptor antibody; N/A, not available.
*Data were expressed as mean fluorescence intensities (MFI).
Table 2. Pathologic Data of Patients
Patient 
ID
Time from  
transplant to Bx
C4d  
grade
Combined pathology
Banff biopsy scoring
(g) (t) (i) (v) (cg) (ct) (ci) (cv) (mm) (ah) (ptc)
A 1 C4d 0 Arteriosclerosis, moderate 0 0 0 0 0 1 1 0 0 0 1
B 1 C4d 0 TG 0 0 1 0 2 0 0 0 0 0 2
C 0 C4d 3 Acute tubular injury 0 0 0 0 0 0 0 0 0 0 0
D 1 C4d 3 Acute tubular injury 1 1 0 0 0 0 0 0 0 0 2
E 0 C4d 3 Diffuse intratubular microcalcification 2 0 0 0 0 1 0 0 0 0 1
F 0 C4d 0 1 0 0 0 0 0 0 0 0 0 2
A 27 C4d 3 1 1 0 1 2 1 0 0 0 0 2
G 120 C4d 3 0 0 1 0 0 1 1 1 0 0 3
H 152 C4d 0 3 0 1 0 3 2 1 0 0 3 1
I 113 C4d 3 1 1 0 0 2 2 1 3 3 3 2
J 262 C4d 2 TG with FSGS 2 0 1 0 3 3 3 2 1 1 1
Bx, biopsy; TG, transplant glomerulopathy; FSGS, focal segmental glomerulosclerosis.
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and angiotensin receptor. However, the antibody-removing ef-
fect of bortezomib was not sustained long-term. Furthermore, 
the treatment effect of bortezomib was more evident in early-
onset AMR than in late-onset AMR. 
In this case series, bortezomib effectively reduced antibod-
ies against various targets, including HLA class I, HLA class II, 
ABO blood group antigen, and AT1R. The majority of studies 
conducted to date have only reported on the effectiveness of 
bortezomib against anti-HLA antibodies.4,5,9 Only a small num-
ber of case reports have described the effect of bortezomib on 
anti-ABO antibody-mediated AMR.15 In the present study, AMR 
caused by anti-AT1R antibodies was included, and treatment 
outcomes were satisfactory. To the best of our knowledge, no 
previous studies have been conducted on the use of bortezo-
mib for the treatment of AMR caused by anti-AT1R antibodies.
The effects of bortezomib on immune response are com-
plex. Endoplasmic reticulum stress and caspase induction are 
considered the primary mechanisms by which bortezomib 
eliminates plasma cells. The inhibition of nuclear factor-kappa B 
activity plays a central role in the anti-humoral activity of bort-
ezomib. In addition, it has been shown to cause apoptosis and 
cell-cycle arrest.3,4 With such a wide range of actions, bortezo-
mib may also have an effect on various kinds of antibodies. 
In view of costs and side-effects, the selection of the correct 
treatment target is important. We analyzed DSHA class (HLA 
class I or II) and complement binding capacity. In the present 
study, preformed antibodies were observed in most early onset 
cases, and antibodies in late onset AMR were predominantly 
directed at HLA class II. These distributions concur with those 
already described.2,5,10 Several studies reported that bortezomib 
has different effects on HLA class I and II antibodies.10 Bortezo-
mib reduces HLA class I–restricted antigen presentation by re-
ducing cell–surface HLA class I expression. However, in the 
present study, most DSHAs were reduced after bortezomib 
treatment regardless of DSHA class. Recently, the complement-
binding capacity of DSHA was found to be an important factor 
of graft injury.16 In the present study, we performed C1q bind-
ing assays to assess the complement binding capacity of DSHA 
retrospectively and found that bortezomib treatment was effec-
tive in AMR with or without C1q-fixing DSHA. However, caution 
is required in generalizing this result due to the small numbers 
of patients involved. Nevertheless, we experienced satisfactory 
treatment outcomes regardless of DSHA class or the comple-
Fig. 1. Changes of renal allograft function after bortezomib treatment ac-
cording to AMR onset time. AMR, antibody-mediated rejection; Dx, diag-
nosis; mo, months.
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Table 3. Changes of Renal Allograft Function and Antibody Levels after Bortezomib Treatment
Patient 
ID
At AMR diagnosis Bortezomib At 3 months after bortezomib Last follow up
Antibodies* C1q Cr eGFR Cycle Dose reduction Antibodies* Cr eGFR Cr eGFR
Duration
(months)
A
A2 (14589), B13 (1365) N/A 4.87 11 1st Peripheral  
  neuropathy
No DSHA 4.23 13
A2 (6738), DR12 (1571) (+) 3.06 18 2nd N/A 1.93 31 2.09 32 10
B
Anti-B IgM/IgG (1:64/1:256)
DR8 (16389)
N/A 5.63 8 1 
Anti-B IgM/IgG (1:16/1:64)
No DSHA
0.95 58 0.93 59 36
C B52 (1063), DR15 (12466) N/A 4.47 11 1 A30 (1068), DR15 (7809) 1.04 57 0.89 68 28
D B27 (12878), DQ9 (17209) (+) 2.31 36 1 DQ9 (11404) 1.24 74 1.37 65 22
E B51 (4136) (-) 2.32 29 1 Thrombocytopenia B51 (2182) 1.24 61 0.86 90 11
F DSHA (-), AT1R Ab >50 U/mL N/A 8.52 7 1 AT1R Ab 11.7 U/mL 2.01 35 1.72 41 10
G DR13 (14274), DQ6 (5148) (-) 4.26 11 2 Thrombocytopenia DR13 (8943), DQ6 (1306) 4.44 11 4.12 12 9
H DR7 (2118), DQ2 (17258) (+) 3.37 20 2 DR7 (2109), DQ2 (21065) 2.55 28 2.46 29 9
I
DSHA (-), Donor CREG  
  Ab-DR13 (11372)
(-) 2.22 23 2 
Donor CREG Ab-DR13  
  (17475)
1.97 26 2.02 25 7
J B13 (9177) (-) 3.7 13 1 B13 (2583), DQ5 (3338) 3.95 12 4.16 11 7
AMR, antibody-mediated rejection; Cr, creatinine; eGFR, estimated glomerular filtration rate; DSHA, donor specific anti-HLA antibodies; N/A, not available; AT1R 
Ab, angiotensin II type 1 receptor antibody; CREG, cross reactive group.
*Data were expressed as mean fluorescence intensities.
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ment-binding capacity of DSHA. 
The time between kidney transplantation and AMR onset 
impacts the treatment effect of bortezomib. In the present 
study, we divided our study group into early-onset AMR and 
late-onset AMR. The six early onset episodes experienced full 
recovery from AMR after one cycle of bortezomib treatment. 
However, late-onset AMR demonstrated a poorer response. 
Three of five patients with late-onset AMR showed improved 
renal allograft function, while the other two did not respond to 
bortezomib treatment. Prior studies have also reported differ-
ent responses for early- and late-onset AMR.5,9 Two explana-
tions have been proposed. First, early-onset AMR is likely to be 
detected early in its course, whereas late-onset AMR is more 
likely to cause irreversible damage due to exposure to harmful 
antibodies for a longer time.5,17 In fact, most of our late-onset 
AMR patients demonstrated transplant glomerulopathy. Sec-
ond, early- and late-onset AMR may differ in terms of plasma 
cell characteristics.5 Future studies are required on this topic.
Despite its wide range of action, the duration of the anti-hu-
moral response to bortezomib was not sustained. We found 
that certain patients experienced de novo antibody formation 
or antibody rebound after bortezomib treatment. According to 
previous studies, antibody titer after transplantation represents 
dynamic change and continues at varying levels thereafter.13,18 
Accordingly, given that antibodies can reoccur, regular moni-
toring of antibody titers is required after bortezomib-based an-
ti-humoral treatment. 
Several limitations of our study require consideration. First, 
the study was limited by a small cohort size, as only eleven epi-
sodes were included. A larger, randomized controlled trial with 
a long-term follow-up is required. Second, given that patients 
received bortezomib after conventional treatments (PP+IVIg+ 
rituximab), it was difficult to assess the contribution of bort-
ezomib to overall efficacy. Third, in the absence of accepted 
guidelines for the evaluation of therapeutic response in the set-
ting of AMR, we evaluated renal function and antibody levels at 
3 months after bortezomib treatment. 
In conclusion, anti-humoral treatment based on bortezomib 
might be an alternative strategy against refractory AMR. De-
spite the small cohort size, our data suggested therapeutic ef-
fectiveness against a wide range of antibodies, including HLA 
antibodies, ABO blood group antibodies, and anti-AT1R anti-
bodies. Finally, bortezomib treatment could be more effective 
in early-onset AMR than in late-onset AMR.
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